InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,383.81
(
0.74%
)
US TECH 100
18,301.00
(
1.36%
)
Dow Jones
39,411.62
(
0.14%
)
Brent Oil
80.82
(
-0.96%
)
Bitcoin
59,548.98
(
0.33%
)
Post# of 252865
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 101525

Wednesday, 09/28/2011 5:12:46 AM

Wednesday, September 28, 2011 5:12:46 AM

Post# of 252865
Astellas terminates development of darexaban (YM150):

http://www.reuters.com/article/2011/09/28/astellas-idUSL3E7KS17D20110928

The decision is not surprising insofar as darexaban was a day late and a dollar short relative to the competition (Xarelto, Eliquis, Pradaxa), as discussed in the prologue of #msg-66651733. Astellas previously submitted an application for marketing approval in Japan (#msg-55022218), but then quietly withdrew the application.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up